International Tech Times
SEE OTHER BRANDS

Your science and technology news reporter

International Tech Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on International Tech Times.

Press releases published on May 7, 2025

ProLogium Collaborates with Kyushu Electric on Next-Gen Batteries for Heavy Machinery

ProLogium Collaborates with Kyushu Electric on Next-Gen Batteries for Heavy Machinery

TAIPEI, Taiwan, May 07, 2025 (GLOBE NEWSWIRE) -- ProLogium Technology, the global leader in LCB-based next-generation battery innovation, today announced a strategic partnership with Japan’s Kyushu Electric Power. Together, the two companies will co- …

Elcogen and Casale SA sign Memorandum of Understanding

Elcogen and Casale SA sign Memorandum of Understanding

TALLINN, Estonia, May 07, 2025 (GLOBE NEWSWIRE) -- Elcogen, a leading European manufacturer of technology that enables the efficient production of affordable green hydrogen and emission-free electricity, today announced that it has entered into a …

UNICOM Engineering Announces Strategic Partnership with E4 Computer Engineering to Deliver Advanced AI Infrastructure Solutions

UNICOM Engineering Announces Strategic Partnership with E4 Computer Engineering to Deliver Advanced AI Infrastructure Solutions

CANTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- UNICOM Engineering announces a strategic partnership with E4 Computer Engineering, the Italian leader in High-Performance Computing (HPC) and AI-driven solutions. This collaboration expands UNICOM Engineering …

Intchains Group Limited to Report Unaudited First Quarter 2025 Financial Results on Thursday, May 22, 2025

Intchains Group Limited to Report Unaudited First Quarter 2025 Financial Results on Thursday, May 22, 2025

SINGAPORE, May 07, 2025 (GLOBE NEWSWIRE) -- Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies, and …

 Prime Biome Reviews Fixed What Doctors Couldn’t – In Just Weeks!  A Reality Based, Self Trial, Facts and Figure Which Revealed the Truth!

Prime Biome Reviews Fixed What Doctors Couldn’t – In Just Weeks! A Reality Based, Self Trial, Facts and Figure Which Revealed the Truth!

St. Petersburg, Florida, May 07, 2025 (GLOBE NEWSWIRE) -- as per studies a person's complete health depends on gut and skin health, especially in our fast-paced environment. People are most concerned about their stomach and skin issues, which can lead to …

Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL

Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL

Improved disease staging tool for hepatic encephalopathy, approved for use by FDA in phase 3 trials of IV ammonia scavenger (YAQ006) Dose-response data of oral ammonia scavenger (YAQ007) for prevention of HE recurrence In vivo demonstration of ammonia …

CLINUVEL recruits 200 patients in  Phase III vitiligo trial CUV105

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

Executive summary Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved Randomised trial, 20-week treatment protocol plus 6-month follow up Study sites in North America, Africa and Europe First clinical …

BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study expected to inform therapeutic strategies beyond ARDS, …

ZenaTech expande su oficina en Irlanda ofreciendo Dron como Servicio (DaaS), incluyendo agricultura de precisión, a un mercado europeo con un crecimiento anual del 28,6%

ZenaTech expande su oficina en Irlanda ofreciendo Dron como Servicio (DaaS), incluyendo agricultura de precisión, a un mercado europeo con un crecimiento anual del 28,6%

VANCOUVER, Columbia Británica, May 06, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), una empresa de tecnología especializada en drones con IA (inteligencia artificial), Dron como un Servicio (DaaS), soluciones …

Hindered Amine Light Stabilizers (HALS) Market worth $2.32 billion by 2030, at a CAGR of 7.01%, says MarketsandMarkets™

Hindered Amine Light Stabilizers (HALS) Market worth $2.32 billion by 2030, at a CAGR of 7.01%, says MarketsandMarkets™

Delray Beach, FL, May 06, 2025 (GLOBE NEWSWIRE) -- In terms of value, the HALS Market is estimated to grow from USD 1.54 billion in 2024 to USD 2.32 billion by 2030, at a CAGR of 7.01%, as per the recent study by MarketsandMarkets™. The market is expanding …

Kirby McInerney LLP Announces Investigation of Claims Against Humana Inc. (HUM) on Behalf of Investors

Kirby McInerney LLP Announces Investigation of Claims Against Humana Inc. (HUM) on Behalf of Investors

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Humana Inc. (“Humana” or the “Company”) (NYSE:HUM). The investigation concerns whether Humana and/or certain of its officers have …

UCTT DEADLINE ALERT: Kirby McInerney LLP Alerts Ultra Clean Holdings, Inc. Investors of Important Lead Plaintiff Deadline in Class Action Lawsuit

UCTT DEADLINE ALERT: Kirby McInerney LLP Alerts Ultra Clean Holdings, Inc. Investors of Important Lead Plaintiff Deadline in Class Action Lawsuit

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP alerts investors of the imminent May 23, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired Ultra …

Kirby McInerney LLP Announces Investigation of Claims Against GoHealth, Inc. (GOCO) on Behalf of Investors

Kirby McInerney LLP Announces Investigation of Claims Against GoHealth, Inc. (GOCO) on Behalf of Investors

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against GoHealth, Inc. (“GoHealth” or the “Company”) (NASDAQ:GOCO). The investigation concerns whether GoHealth and/or certain of its officers …

Kirby McInerney LLP Announces Investigation of Claims Against SelectQuote, Inc. (SLQT) on Behalf of Investors

Kirby McInerney LLP Announces Investigation of Claims Against SelectQuote, Inc. (SLQT) on Behalf of Investors

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against SelectQuote, Inc. (“SelectQuote” or the “Company”) (NYSE:SLQT). The investigation concerns whether SelectQuote and/or certain of its …

Kirby McInerney LLP Announces Investigation of Claims Against CVS Health Corporation (CVS) on Behalf of Investors

Kirby McInerney LLP Announces Investigation of Claims Against CVS Health Corporation (CVS) on Behalf of Investors

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against CVS Health Corporation (“CVS” or the “Company”) (NYSE:CVS). The investigation concerns whether CVS and/or certain of its officers have …

Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference

Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference

Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery Preclinical data demonstrates sustained efficacy and safety for six months or more following …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions